These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 27571745

  • 1. Osteoprotective effects of osthole in a mouse model of 5/6 nephrectomy through inhibiting osteoclast formation.
    Li X, Xue C, Wang L, Tang D, Huang J, Zhao Y, Chen Y, Zhao D, Shi Q, Wang Y, Shu B.
    Mol Med Rep; 2016 Oct; 14(4):3769-76. PubMed ID: 27571745
    [Abstract] [Full Text] [Related]

  • 2. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [Abstract] [Full Text] [Related]

  • 3. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.
    Biochem Pharmacol; 2013 Sep 15; 86(6):782-90. PubMed ID: 23928189
    [Abstract] [Full Text] [Related]

  • 4. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.
    J Bone Miner Res; 2005 Sep 15; 20(9):1659-68. PubMed ID: 16059637
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT, Park DH, Kim O, Kwon SH, Min BS, Lee JH.
    Int J Mol Med; 2018 Jul 15; 42(1):569-578. PubMed ID: 29693149
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J.
    Clin Exp Rheumatol; 2008 Jul 15; 26(2):295-304. PubMed ID: 18565252
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
    Kitamura K, Takahira K, Inari M, Satoh Y, Hayakawa K, Tabuchi Y, Ogai K, Nishiuchi T, Kondo T, Mikuni-Takagaki Y, Chen W, Hattori A, Suzuki N.
    Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep 15; 166(1):74-80. PubMed ID: 23632157
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
    Peng S, Liu XS, Zhou G, Li Z, Luk KD, Guo XE, Lu WW.
    J Bone Miner Res; 2011 Jun 15; 26(6):1272-82. PubMed ID: 21611968
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.
    Bone; 2015 Oct 15; 79():242-51. PubMed ID: 26103094
    [Abstract] [Full Text] [Related]

  • 16. Leonurus sibiricus L. ethanol extract promotes osteoblast differentiation and inhibits osteoclast formation.
    Kim JH, Kim M, Jung HS, Sohn Y.
    Int J Mol Med; 2019 Sep 15; 44(3):913-926. PubMed ID: 31524244
    [Abstract] [Full Text] [Related]

  • 17. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
    Cheon YH, Kim JY, Baek JM, Ahn SJ, Jun HY, Erkhembaatar M, Kim MS, Lee MS, Oh J.
    J Bone Miner Res; 2016 Feb 15; 31(2):403-15. PubMed ID: 26255791
    [Abstract] [Full Text] [Related]

  • 18. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
    Fioramonti M, Santini D, Iuliani M, Ribelli G, Manca P, Papapietro N, Spiezia F, Vincenzi B, Denaro V, Russo A, Tonini G, Pantano F.
    Oncotarget; 2017 Mar 21; 8(12):20113-20121. PubMed ID: 28223547
    [Abstract] [Full Text] [Related]

  • 19. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
    Jia P, He YF, Gao C, Du HB, Hu ZY, Feng XQ, Li BY, Zhang ZL, Xu YJ, Lin H.
    Zhonghua Yi Xue Za Zhi; 2012 Aug 21; 92(31):2214-8. PubMed ID: 23158430
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
    Song R, Gu J, Liu X, Zhu J, Wang Q, Gao Q, Zhang J, Cheng L, Tong X, Qi X, Yuan Y, Liu Z.
    Int J Mol Med; 2014 Sep 21; 34(3):856-62. PubMed ID: 25017214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.